Advanced search
Publication Cover
International Medical Case Reports Journal Volume 16, 2023 - Issue
Submit an article Journal homepage
301
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

Diagnostic and Therapeutic Challenges of Chronic Portal Vein Thrombosis Secondary to Myeloproliferative Neoplasm in Sub-Saharan Region: A Series of Cases and Literature Review

Abdu Mohammed1 Department of Internal Medicine, Adera Medical Center, Addis Ababa, EthiopiaCorrespondence[email protected]
,
Abate Bane Shewaye1 Department of Internal Medicine, Adera Medical Center, Addis Ababa, Ethiopia;2 Department of internal Medicine, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia
,
Fozia Abdela1 Department of Internal Medicine, Adera Medical Center, Addis Ababa, Ethiopia;2 Department of internal Medicine, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia
,
Zebeaman Tibebu Gorfu1 Department of Internal Medicine, Adera Medical Center, Addis Ababa, Ethiopia
&
Ahmed Adem1 Department of Internal Medicine, Adera Medical Center, Addis Ababa, Ethiopia;2 Department of internal Medicine, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia
Pages 13-25 | Received 05 Aug 2022, Accepted 20 Dec 2022, Published online: 05 Jan 2023

References

  • De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K. Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. Am J Roentgenol. 2013;165(5):1151–1155. doi:10.2214/AJR.165.5.7572494
  • Wei B, Huang Z, Tang C. Optimal treatment for patients with cavernous transformation of the portal vein. Front Med. 2022;9:657. doi:10.3389/FMED.2022.853138/BIBTEX
  • Kelliher S, Falanga A. Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thrombosis Update. 2021;5:100081. doi:10.1016/J.TRU.2021.100081
  • Elkrief L, Houssel-Debry P, Ackermann O, et al. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction. Clin Res Hepatol Gastroenterol. 2020;44(4):491–496. doi:10.1016/J.CLINRE.2020.03.016
  • Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179–202. doi:10.1016/j.jhep.2015.07.040
  • Hajdu CH, Murakami T, Diflo T, et al. Intrahepatic portal cavernoma as an indication for liver transplantation. Liver Transplant. 2007;13(9):1312–1316. doi:10.1002/LT.21243
  • Greenfield G, McMullin MF. Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series. Thromb J. 2018;16(1):33. doi:10.1186/s12959-018-0187-z
  • How J, Trinkaus KM, Oh ST. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. Br J Haematol. 2018;183(2):310–313. doi:10.1111/bjh.14958
  • Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study. Liver Int. 2019;39(8):1459–1467. doi:10.1111/liv.14121
  • Dhiman RK, Saraswat VA, Valla DC, et al. Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian National Association for study of the liver. J Clin Exp Hepatol. 2014;4(Suppl 1):S2. doi:10.1016/J.JCEH.2014.02.003
  • Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–4928. doi:10.1182/blood-2011-09-376517
  • Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176–2184. doi:10.1182/BLOOD-2013-03-460154
  • Sedhom WG, Stein BL. Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: the drug and the duration. Hemato. 2021;2(2):255–263. doi:10.3390/hemato2020015
  • de Stefano V, Vannucchi AM, Ruggeri M, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493–e493. doi:10.1038/bcj.2016.103
  • Riva N, Ageno W, Poli D, et al. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thrombosis Haemostasis. 2015;13(6):1019–1027. doi:10.1111/jth.12930
  • Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv. 2020;4(4):655–666. doi:10.1182/bloodadvances.2019001310
  • Debureaux PE, Cassinat B, Soret-Dulphy J, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv. 2020;4(15):3708–3715. doi:10.1182/BLOODADVANCES.2020002414
  • de Stefano V, Rossi E, Carobbio A, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8(11). doi:10.1038/s41408-018-0151-y

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.